Literature DB >> 25586123

Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective.

Tomas Jernberg1, Pål Hasvold2, Martin Henriksson2, Hans Hjelm3, Marcus Thuresson4, Magnus Janzon5.   

Abstract

AIMS: Long-term disease progression following myocardial infarction (MI) is not well understood. We examined the risk of subsequent cardiovascular events in patients discharged after MI in Sweden. METHODS AND
RESULTS: This was a retrospective, cohort study linking morbidity, mortality, and medication data from Swedish national registries. Of 108 315 patients admitted to hospital with a primary MI between 1 July 2006 and 30 June 2011 (index MI), 97 254 (89.8%) were alive 1 week after discharge and included in this study. The primary composite endpoint of risk for non-fatal MI, non-fatal stroke, or cardiovascular death was estimated for the first 365 days post-index MI and Day 366 to study completion. Risk and risk factors were assessed by Kaplan-Meier analysis and Cox proportional hazards modelling, respectively. Composite endpoint risk was 18.3% during the first 365 days post-index MI. Age [60-69 vs. <60 years: HR (95% CI): 1.37 (1.30-1.45); 70-79 vs. <60 years: 2.13 (2.03-2.24); >80 vs. <60 years: 3.96 (3.78-4.15)], prior MI [1.44 (1.40-1.49)], stroke [1.49 (1.44-1.54)], diabetes [1.37 (1.34-1.40)], heart failure [1.57 (1.53-1.62)] and no index MI revascularisation [1.88 (1.83-1.93)] were each independently associated with a higher risk of ischaemic events or death. For patients without a combined endpoint event during the first 365 days, composite endpoint risk was 20.0% in the following 36 months.
CONCLUSIONS: Risk of cardiovascular events appeared high beyond the first year post-MI, indicating a need for prolonged surveillance, particularly in patients with additional risk factors. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2015. For permissions please email: journals.permissions@oup.com.

Entities:  

Keywords:  Mortality; Myocardial infarction; Nationwide register data; Prognosis; Risk factors

Mesh:

Year:  2015        PMID: 25586123     DOI: 10.1093/eurheartj/ehu505

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  181 in total

Review 1.  Intrinsic Vascular Repair by Endothelial Progenitor Cells in Acute Coronary Syndromes: an Update Overview.

Authors:  Vânia Leal; Carlos Fontes Ribeiro; Bárbara Oliveiros; Natália António; Sónia Silva
Journal:  Stem Cell Rev Rep       Date:  2019-02       Impact factor: 5.739

Review 2.  Anticoagulant Therapy for Acute Coronary Syndromes.

Authors:  Eunice Nc Onwordi; Amr Gamal; Azfar Zaman
Journal:  Interv Cardiol       Date:  2018-05

Review 3.  Changes and innovations of the 2017 ESC guidelines on dual antiplatelet therapy in coronary artery disease-a review.

Authors:  Hannes F Alber; Kurt Huber
Journal:  Wien Klin Wochenschr       Date:  2018-07-20       Impact factor: 1.704

4.  Flow Perturbation Mediates Neutrophil Recruitment and Potentiates Endothelial Injury via TLR2 in Mice: Implications for Superficial Erosion.

Authors:  Grégory Franck; Thomas Mawson; Grasiele Sausen; Manuel Salinas; Gustavo Santos Masson; Andrew Cole; Marina Beltrami-Moreira; Yiannis Chatzizisis; Thibault Quillard; Yevgenia Tesmenitsky; Eugenia Shvartz; Galina K Sukhova; Filip K Swirski; Matthias Nahrendorf; Elena Aikawa; Kevin J Croce; Peter Libby
Journal:  Circ Res       Date:  2017-04-20       Impact factor: 17.367

Review 5.  Role of Heat Shock Protein 27 in Modulating Atherosclerotic Inflammation.

Authors:  Jose A Inia; Edward R O'Brien
Journal:  J Cardiovasc Transl Res       Date:  2020-07-13       Impact factor: 4.132

6.  Outcomes in patients after myocardial infarction similar to those of the PEGASUS-TIMI 54 trial: A cohort study in the French national claims database.

Authors:  Patrick Blin; Caroline Dureau-Pournin; Régis Lassalle; Jérémy Jové; Florence Thomas-Delecourt; Cécile Droz-Perroteau; Nicolas Danchin; Nicholas Moore
Journal:  Br J Clin Pharmacol       Date:  2017-05-05       Impact factor: 4.335

7.  Concomitant use of drugs known to cause interactions with oral antiplatelets-polypharmacy in acute coronary syndrome outpatients in Finland.

Authors:  Tuire Prami; Houssem Khanfir; Pål Hasvold; Eeva Reissell; Juhani Airaksinen; Ville Kytö
Journal:  Eur J Clin Pharmacol       Date:  2019-11-26       Impact factor: 2.953

Review 8.  [Hypercholesterolemia - Where are we today? Where are we going?].

Authors:  A K Gitt; R Zahn
Journal:  Herz       Date:  2016-07-13       Impact factor: 1.443

9.  Atherosclerosis: Successes, Surprises, and Future Challenges.

Authors:  Peter Libby; Karin E Bornfeldt; Alan R Tall
Journal:  Circ Res       Date:  2016-02-19       Impact factor: 17.367

10.  Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction.

Authors:  Robert W Yeh; Dean J Kereiakes; Philippe Gabriel Steg; Stephan Windecker; Michael J Rinaldi; Anthony H Gershlick; Donald E Cutlip; David J Cohen; Jean-Francois Tanguay; Alice Jacobs; Stephen D Wiviott; Joseph M Massaro; Adrian C Iancu; Laura Mauri
Journal:  J Am Coll Cardiol       Date:  2015-03-15       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.